GH Research (GHRS) experimenta un aumento del 22% debido al permiso de la FDA para el uso del medicamento contra la depresión. ¿Será este el catalizador que impulse el desarrollo de los psicodélicos en el futuro?

Summary
• GH Research’s stock (GHRS) rockets 21.99% intraday to $17.225, breaking above its 52-week high of $20.50.
• FDA lifts clinical hold on GH001, clearing the path for global Phase 3 trials in 2026.
• Analysts project a 126.59% upside, with price targets ranging from $19 to $39.
• Turnover surges to 949,114 shares, reflecting intense retail and institutional interest.

GH Research’s stock has erupted on news of the FDA’s regulatory green light for its depression treatment GH001, sparking a 22% intraday rally. The move follows months of anticipation around Phase 3 trial readiness and a 73% remission rate in Phase 2b data. With the stock trading near its 52-week high and analysts bullish on long-term potential, the question now is whether this is a sustainable breakout or a short-lived spike.

FDA Approval Clears the Path for GH001’s Global Expansion
The FDA’s decision to lift the clinical hold on GH001 has ignited investor enthusiasm. This regulatory milestone, announced in a SEC filing, allows GH Research to proceed with Phase 3 trials in 2026, a critical step toward commercialization. The company highlighted a 73% remission rate in its Phase 2b trial with no serious adverse events, reinforcing safety and efficacy. Additionally, positive analyst sentiment—seven out of nine Wall Street analysts have issued 'buy' ratings—has amplified the stock’s momentum. The move aligns with broader psychedelics sector optimism, as investors bet on the therapeutic potential of 5-MeO-DMT-based treatments.

Biotech Sector Rally: AMGN’s 3.55% Gain Reflects Broader Optimism
The biotechnology sector has shown resilience, with Amgen (AMGN) rising 3.55% on the same day. While GH Research’s surge is driven by regulatory progress, the sector’s overall strength—bolstered by advancements in gene therapy and obesity treatments—creates a favorable backdrop. Sectors like cell and gene therapy (e.g., Soley’s $200M Series C) and antifungal development (Basilea’s collaboration) highlight the industry’s innovation. GH Research’s focus on psychedelic therapies positions it as a niche but high-growth player within this dynamic landscape.

Options Playbook: Leveraging GHRS’s Volatility with High-Gamma Contracts
• MACD: -0.038 (bullish crossover), Signal Line: -0.238, Histogram: 0.200 (positive divergence)
• RSI: 65.07 (overbought but not extreme), Bollinger Bands: Upper $14.97, Middle $13.26, Lower $11.56 (price above middle band)
• 200D MA: $12.87 (price significantly above), 30D MA: $13.72 (support zone at $12.66–$12.72)

GHRS’s technicals suggest a continuation of its bullish trend. The RSI’s 65.07 reading indicates overbought conditions, but the MACD’s positive divergence and price above the 200D MA signal sustained momentum. Key levels to watch include the 52-week high of $20.50 and the 200D MA at $12.87. With implied volatility (IV) surging to 347.22% on the GHRS20260116C17.5 contract, options traders can capitalize on short-term volatility.

Top Options Picks:
• GHRS20260116C17.5 (Call):
- Strike: $17.50, Expiration: 2026-01-16, IV: 70.33%, Delta: 0.4996, Theta: -0.0734, Gamma: 0.1974, Turnover: 274
- IV (70.33%) suggests moderate volatility, Delta (0.4996) balances sensitivity and leverage, Gamma (0.1974) ensures responsiveness to price swings. A 5% upside to $18.08 would yield a payoff of $0.58 per contract.
• GHRS20260220C17.5 (Call):
- Strike: $17.50, Expiration: 2026-02-20, IV: 71.01%, Delta: 0.5450, Theta: -0.0263, Gamma: 0.0916, Turnover: 980
- IV (71.01%) and Delta (0.5450) position this as a mid-term play. Gamma (0.0916) ensures gradual acceleration. A 5% move to $18.08 would generate a $0.58 payoff. High turnover (980) ensures liquidity.

Actionable Insight: Aggressive bulls should target GHRS20260116C17.5 for a short-term pop, while GHRS20260220C17.5 offers a balanced mid-term play. Watch for a break above $18.50 to validate the bullish case.

Backtest GH Research Stock Performance
The backtest of GHRS's performance following a 22% intraday increase from 2022 to the present reveals mixed results. While the stock experienced a maximum return of 8.86% on January 7, 2026, which is below the 22% surge, the 3-day win rate is 48.68%, the 10-day win rate is 51.98%, and the 30-day win rate is 52.86%. These rates suggest that GHRS has a higher probability of positive returns in the short term, but the actual returns have been relatively modest compared to the potential increase.

GHRS’s FDA Win: A Catalyst for Long-Term Growth or a Short-Squeeze Play?
GH Research’s 22% surge on FDA approval signals a pivotal moment for its GH001 program. With Phase 3 trials now on track and a 73% remission rate in Phase 2b data, the stock has the fundamentals to sustain its rally. Technicals—MACD divergence, RSI overbought but not extreme, and price above key moving averages—support a continuation. However, high implied volatility in options like GHRS20260116C17.5 suggests short-term risks. Investors should monitor the 52-week high of $20.50 and the sector leader Amgen (AMGN) at +3.55% for broader biotech cues. For now, GHRS’s momentum is a must-watch, with options offering leveraged access to its next move.